• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中文译文:用于乳腺癌发病率和死亡率的临床预测模型的开发和验证:一项双队列研究方案。

Development and validation of clinical prediction models for breast cancer incidence and mortality: a protocol for a dual cohort study.

机构信息

Cancer Research UK Oxford Centre, University of Oxford, Oxford, UK

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

出版信息

BMJ Open. 2022 Mar 28;12(3):e050828. doi: 10.1136/bmjopen-2021-050828.

DOI:10.1136/bmjopen-2021-050828
PMID:35351695
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8961149/
Abstract

INTRODUCTION

Breast cancer is the most common cancer and the leading cause of cancer-related death in women worldwide. Risk prediction models may be useful to guide risk-reducing interventions (such as pharmacological agents) in women at increased risk or inform screening strategies for early detection methods such as screening.

METHODS AND ANALYSIS

The study will use data for women aged 20-90 years between 2000 and 2020 from QResearch linked at the individual level to hospital episodes, cancer registry and death registry data. It will evaluate a set of modelling approaches to predict the risk of developing breast cancer within the next 10 years, the 'combined' risk of developing a breast cancer and then dying from it within 10 years, and the risk of breast cancer mortality within 10 years of diagnosis. Cox proportional hazards, competing risks, random survival forest, deep learning and XGBoost models will be explored. Models will be developed on the entire dataset, with 'apparent' performance reported, and internal-external cross-validation used to assess performance and geographical and temporal transportability (two 10-year time periods). Random effects meta-analysis will pool discrimination and calibration metric estimates from individual geographical units obtained from internal-external cross-validation. We will then externally validate the models in an independent dataset. Evaluation of performance heterogeneity will be conducted throughout, such as exploring performance across ethnic groups.

ETHICS AND DISSEMINATION

Ethics approval was granted by the QResearch scientific committee (reference number REC 18/EM/0400: OX129). The results will be written up for submission to peer-reviewed journals.

摘要

简介

乳腺癌是全球最常见的癌症,也是导致女性癌症相关死亡的主要原因。风险预测模型可能有助于指导高风险女性的降低风险干预措施(如药物治疗),或为早期检测方法(如筛查)提供信息以制定筛查策略。

方法和分析

该研究将使用 2000 年至 2020 年期间 QResearch 中年龄在 20 至 90 岁之间的女性个体数据,这些数据与医院就诊记录、癌症登记和死亡登记数据进行了个体水平的链接。它将评估一系列建模方法,以预测未来 10 年内乳腺癌发病风险、10 年内发生乳腺癌并因此死亡的“综合”风险,以及诊断后 10 年内乳腺癌死亡率的风险。将探索 Cox 比例风险、竞争风险、随机生存森林、深度学习和 XGBoost 模型。将在整个数据集上开发模型,并报告“明显”的性能,同时使用内部-外部交叉验证来评估性能以及地理和时间可转移性(两个 10 年时间区间)。将从内部-外部交叉验证中获得的个体地理单元的区分度和校准度量估计值进行随机效应荟萃分析进行汇总。然后,将在独立数据集之外验证模型。整个过程中都将对性能异质性进行评估,例如探索不同种族群体之间的性能。

伦理与传播

QResearch 科学委员会已批准该研究(参考编号 REC 18/EM/0400: OX129)。研究结果将被撰写并提交给同行评审期刊。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e86/8961149/0e151a3fb477/bmjopen-2021-050828f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e86/8961149/0e151a3fb477/bmjopen-2021-050828f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e86/8961149/0e151a3fb477/bmjopen-2021-050828f01.jpg

相似文献

1
Development and validation of clinical prediction models for breast cancer incidence and mortality: a protocol for a dual cohort study.中文译文:用于乳腺癌发病率和死亡率的临床预测模型的开发和验证:一项双队列研究方案。
BMJ Open. 2022 Mar 28;12(3):e050828. doi: 10.1136/bmjopen-2021-050828.
2
Predicting 10-year breast cancer mortality risk in the general female population in England: a model development and validation study.预测英格兰普通女性人群 10 年乳腺癌死亡率:模型开发和验证研究。
Lancet Digit Health. 2023 Sep;5(9):e571-e581. doi: 10.1016/S2589-7500(23)00113-9.
3
Development and internal-external validation of statistical and machine learning models for breast cancer prognostication: cohort study.统计和机器学习模型在乳腺癌预后预测中的开发和内外验证:队列研究。
BMJ. 2023 May 10;381:e073800. doi: 10.1136/bmj-2022-073800.
4
Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19·67 million people and evaluation of model performance against seven other risk prediction models.预测肺癌未来风险:CanPredict(肺部)模型在 1967 万人中的开发、内部和外部验证以及该模型与其他七个风险预测模型的性能评估。
Lancet Respir Med. 2023 Aug;11(8):685-697. doi: 10.1016/S2213-2600(23)00050-4. Epub 2023 Apr 5.
5
Validation and development of models using clinical, biochemical and ultrasound markers for predicting pre-eclampsia: an individual participant data meta-analysis.利用临床、生化和超声标志物预测子痫前期的模型的验证和建立:一项个体参与者数据荟萃分析。
Health Technol Assess. 2020 Dec;24(72):1-252. doi: 10.3310/hta24720.
6
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
7
10-year performance of four models of breast cancer risk: a validation study.四种乳腺癌风险模型的 10 年表现:一项验证研究。
Lancet Oncol. 2019 Apr;20(4):504-517. doi: 10.1016/S1470-2045(18)30902-1. Epub 2019 Feb 21.
8
Development and validation of prediction models for fetal growth restriction and birthweight: an individual participant data meta-analysis.胎儿生长受限和出生体重预测模型的建立与验证:个体参与者数据的荟萃分析。
Health Technol Assess. 2024 Aug;28(47):1-119. doi: 10.3310/DABW4814.
9
A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance.基于荟萃分析的乳腺癌发病风险预测模型的系统评价。
Breast Cancer Res Treat. 2012 Apr;132(2):365-77. doi: 10.1007/s10549-011-1818-2. Epub 2011 Oct 22.
10
Development and validation of a new predictive model for breast cancer survival in New Zealand and comparison to the Nottingham prognostic index.开发和验证新西兰乳腺癌生存的新预测模型,并与诺丁汉预后指数进行比较。
BMC Cancer. 2018 Sep 17;18(1):897. doi: 10.1186/s12885-018-4791-x.

引用本文的文献

1
Blocking or knockdown of P2X7 receptor inhibits invasion and migration of mouse breast cancer cells via PI3K/Akt/GSK-3β pathways and EMT.P2X7受体的阻断或敲低通过PI3K/Akt/GSK-3β信号通路和上皮-间质转化抑制小鼠乳腺癌细胞的侵袭和迁移。
Med Oncol. 2025 Jul 16;42(8):340. doi: 10.1007/s12032-025-02932-w.
2
Development and Validation of a Lifestyle-Based 10-Year Risk Prediction Model of Colorectal Cancer for Early Stratification: Evidence from a Longitudinal Screening Cohort in China.基于生活方式的结直肠癌10年风险预测模型的开发与验证用于早期分层:来自中国纵向筛查队列的证据
Nutrients. 2025 May 31;17(11):1898. doi: 10.3390/nu17111898.
3

本文引用的文献

1
Prostate-specific antigen testing and opportunistic prostate cancer screening: a cohort study in England, 1998-2017.基于队列的英格兰地区研究 1998-2017:前列腺特异性抗原检测与机会性前列腺癌筛查
Br J Gen Pract. 2021 Jan 28;71(703):e157-e165. doi: 10.3399/bjgp20X713957. Print 2021.
2
Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study.成人因冠状病毒 19 住院和死亡风险的生存风险预测算法(QCOVID):全国推导和验证队列研究。
BMJ. 2020 Oct 20;371:m3731. doi: 10.1136/bmj.m3731.
3
Transparency and reproducibility in artificial intelligence.
A plea for more careful scholarship in reviewing evidence: the case of mammographic screening.
呼吁在审查证据时进行更严谨的学术研究:以乳腺钼靶筛查为例。
BJR Open. 2023 Sep 25;5(1):20230041. doi: 10.1259/bjro.20230041. eCollection 2023.
4
Validating a model for predicting breast cancer and nonbreast cancer death in women aged 55 years and older.验证一个预测 55 岁及以上女性乳腺癌和非乳腺癌死亡的模型。
J Natl Cancer Inst. 2024 Jan 10;116(1):81-96. doi: 10.1093/jnci/djad188.
5
Development and internal-external validation of statistical and machine learning models for breast cancer prognostication: cohort study.统计和机器学习模型在乳腺癌预后预测中的开发和内外验证:队列研究。
BMJ. 2023 May 10;381:e073800. doi: 10.1136/bmj-2022-073800.
人工智能中的透明度和可重复性。
Nature. 2020 Oct;586(7829):E14-E16. doi: 10.1038/s41586-020-2766-y. Epub 2020 Oct 14.
4
Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score.利用 ISARIC WHO 临床特征协议对因 COVID-19 住院的患者进行风险分层:4C 死亡率评分的制定和验证。
BMJ. 2020 Sep 9;370:m3339. doi: 10.1136/bmj.m3339.
5
Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History.基于多基因风险和家族史的个体化乳腺癌筛查。
J Natl Cancer Inst. 2021 Apr 6;113(4):434-442. doi: 10.1093/jnci/djaa127.
6
Multiple imputation with missing indicators as proxies for unmeasured variables: simulation study.缺失指标的多重插补作为未测量变量的代理:模拟研究。
BMC Med Res Methodol. 2020 Jul 8;20(1):185. doi: 10.1186/s12874-020-01068-x.
7
Personalized early detection and prevention of breast cancer: ENVISION consensus statement.乳腺癌个体化早期检测和预防:ENVISION 共识声明。
Nat Rev Clin Oncol. 2020 Nov;17(11):687-705. doi: 10.1038/s41571-020-0388-9. Epub 2020 Jun 18.
8
Risk stratification in breast cancer screening: Cost-effectiveness and harm-benefit ratios for low-risk and high-risk women.乳腺癌筛查中的风险分层:低危和高危女性的成本效益和危害-获益比。
Int J Cancer. 2020 Dec 1;147(11):3059-3067. doi: 10.1002/ijc.33126. Epub 2020 Jun 30.
9
Machine learning and artificial intelligence research for patient benefit: 20 critical questions on transparency, replicability, ethics, and effectiveness.机器学习和人工智能研究如何造福患者:透明度、可重复性、伦理和有效性方面的 20 个关键问题。
BMJ. 2020 Mar 20;368:l6927. doi: 10.1136/bmj.l6927.
10
Calibration: the Achilles heel of predictive analytics.校准:预测分析的阿喀琉斯之踵。
BMC Med. 2019 Dec 16;17(1):230. doi: 10.1186/s12916-019-1466-7.